Dimerix Limited · ASX:DXB
Dimerix — Shareholder Meeting (September 2021)
18 slides from Dimerix's shareholder meeting presentation, Sep 27, 2021
Slide 1: AGM Presentation – Board and management
For personal use only Bronwyn Robert Nina Hamish Product Development R&D Director CEO & MD CFO & Co.Sec Director
Slide 2: Forward looking statements
Forward looking statements This presentation includes forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks and important factors that may cause the actual results, performance or achievements of Dimerix to be materially different fro
Slide 3: Key achievements — FY21
Key achievements — FY21 4 al v Phase 3 study in FSGS designed and | vi he preparing to initiate, with other pipeline products also progressing ._ Y Two independent Phase 3 clinical Pal > studies underway in patients with Pe .) COVID-19 respiratory complications nid oe \ q v DMX-200 manufacturing pro
Slide 4: Product candidates in the pipeline, with clinical opportunities
5 product candidates in the pipeline, with 4 clinical opportunities For personal use only
Slide 5: For personal use only
oa) Cc 0) = QO © oO > od) A i Cc od) ~ = ® 2 oO > O Ajuo esn feuosied 10}
Slide 6: Why FSGS: unmet need and market potential
Why FSGS: unmet need and market potential 80,500 estimated in US 210,000 FSGS FSGS: rare kidney disease characterized by inflammation and sufferers globally# scarring of the kidney’s filtration units, affecting children and adults >16,000 new cases diagnosed/year* Renal failure in <5 years from diag
Slide 7: FSGS Phase 3 study primary endpoint
FSGS phase 3 study primary endpoint A randomised, double-blind, multi-centre, placebo-controlled study of renal outcomes of DMX-200 in patients with primary FSGS receiving an ARB Single, seamless Phase 3 study design* n="180* Group 1 DMX-200 + ARB DMX-200 + ARB DMX-200 + ARB Group 2 ARB only ARB onl
Slide 8: COVID-19 Respiratory Complications
COVID-19 Respiratory Complications * For personai™ise Ona a
Slide 9: Vaccines very important but may not be sufficient
Vaccines very important but may not be sufficient to meet the virus challenges DMX-200 * Company’s approach is approach is based on a clear scientific rationale, unique & potentially complementary to others being investigated globally * If effective, could be equally effective against any strain as
Slide 10: COVID-19 and pneumonia market potential
COVID-19 and pneumonia market potential 20-30% of all patients with pneumonia require admission to Intensive Care Units* 50 % Pneumonia is responsible for half of all cases of sepsis and septic shock* 3 million Deaths annually caused by lower respiratory tract infections pre-COVID* US$17 billion Pre
Slide 11: For personal use only
For personal use only • • • Secondary endpoint: recovery and quality of life post hospitalisation (long-COVID assessment) • •
Slide 12: Additional longer term propositions
Additional longer term propositions
Slide 13: Additional asset value propositions
Additional asset value propositions Chronic Obstructive Pulmonary Disease Diabetic Kidney Disease Global COPD treatment market (2017) Addressable market “US$14 billion “US$1.1 billion Key driver is the rise in diabetes global incidence Dimerix 13
Slide 14: Outcomes & Value Driving Events
For personal use only mlatclalelt) Outcomes & Value Driving Events
Slide 15: FY2021 financial outcomes
FY20721 financial outcomes ™ R&D Investment Other Operating Costs $9,332,356 2021 $1,559,841 2020 Cash Reserve we had at Amount we invested in our product SE June 2021 portfolio in FY2021 soa $5.3 million* $9.3 million $1,265,441 2018 aa The number of Phase 2 The number of Phase 3 stage $1,418,810 c
Slide 16: Top shareholders
For personal use only Top shareholders**
Slide 17: For personal use only
For personal use only ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ❑ ❑ ❑ ❑ ❑ ❑ ❑ ❑
Slide 18: Questions?
Questions? @ Dimerix “We are profoundly aware of the potential impact Dimerix may have in improving the lives of millions of people around the world with both respiratory and renal conditions” Dr Nina Webster CEO & Managing Director 18